Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP9EJ7)

• Drug Name: CM-2236 Drug Info
• Synonyms: Psychomodulator (post-traumatic stress disorder), Cenomed BioSciences

Indication

Disease Entry	ICD 11	Status	REF
Post-traumatic stress disorder	6B40	Preclinical	[1]

• Cross-matching ID: TTD Drug ID: DMP9EJ7

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[3]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[4]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[5]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[6]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[8]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[9]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[10]
Treximet	DMU54QB	Migraine	8A80	Approved	[11]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[12]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[13]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[13]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[3]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[14]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[11]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[15]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[16]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[17]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[17]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[2]
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Agonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029346)
• [2] CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [5] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [6] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [9] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [10] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [13] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [14] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [15] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
• [16] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [17] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [18] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.